Regulus Therapeutics Announces Receipt Of FDA Orphan Drug Designation For Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc (RGLS) - Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd).
